ArticleJournal of gastrointestinal oncology2025
Efficacy and safety of tyrosine kinase inhibitors combined with sintilimab and transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma: a pooled analysis.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trials on tyrosine kinase inhibitors combined with sintilimab and transarterial chemoembolization (TKIs-Sin-TACE) for the treatment of unresectable hepatocellular carcinoma (HCC) are ongoing and show promising results. However, the number of participants recruited so far has been relatively limited. This pooled analysis aims to evaluate the efficacy and safety of TKIs-Sin-TACE in patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC. Methods: To obtain potentially eligible studies, databases such as PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched up to October 1, 2024. The Methodological Index for Non-Randomized Studies (MINORS) was used to evaluate literature quality and the levels of bias. A random-effects model was utilized to calculate the pooled rate and confidence interval (CI). Results: This study included six studies involving a total of 336 patients with HCC at BCLC stage B/C. Regarding efficacy, the pooled objective response rate, disease control rate, integrated rates for 10-month progression-free survival, 10-month overall survival (OS), 20-month OS were 39% (95% CI: 26-55%),74% (95% CI: 60-84%),41% (95% CI: 30-54%), and 73% (95% CI: 54-86%), 30% (95% CI: 16-49%), respectively. Regarding safety, the aggregated incidence of treatment-related adverse events ≥ grade 3 was 23% (95% CI: 12-42%). Conclusions: TKIs-Sin-TACE exhibits an efficacious and safe profile for Chinese patients with BCLC stage B/C HCC. Large-scale, global multicenter randomized-controlled trials are needed to further validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.